Abstract #3924

MRS measurement of succinate in vivo as a biomarker in succinate dehydrogenase deficient tumours

Mary A McLean¹, Ruth T Casey^2,3, Benjamin G Challis³, Rogier ten Hoopen⁴, Thomas Roberts⁵, Graeme R Clark², Deborah Pittfield³, Helen L Simpson⁶, Venkata R Bulusu⁷, Kieran Allinson⁸, Lisa Happerfield⁹, Soo-Mi Park², Alison Marker⁸, Olivier Giger⁴, Basetti Madhu¹, Eamonn R Maher², and Ferdia A Gallagher¹⁰

¹Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom, ²Medical Genetics, University of Cambridge, Cambridge, United Kingdom, ³Endocrinology, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom, ⁴Pathology, University of Cambridge, Cambridge, United Kingdom, ⁵Haematology Oncology, University of Cambridge, Cambridge, United Kingdom, ⁶Diabetes and Endocrinology, UCLH NHS Foundation Trust, London, United Kingdom, ⁷Medical Oncology, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom, ⁸Histopathology, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom, ⁹Immunohistochemistry, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom, ¹⁰Radiology, University of Cambridge, Cambridge, United Kingdom

We performed respiratory-gated single-voxel ¹H-MRS (TE = 144ms; voxel size 2.2-100ml; 96-512 averages) at 3T in tumours with suspected mutations in the mitochondrial enzyme succinate dehydrogenase (SDH) in 15 patients, analysed using LCModel. A germline mutation or epimutation in one of the SDH genes was identified in 11/15 subjects, with concordant MRS findings in 9 subjects, data rejection as technical failure in 4, and equivocal results in 2. Referencing succinate peaks to choline was an important quality control for discrimination of true from false negatives. MRS may provide a useful biomarker of SDH activity in this patient group.

This abstract and the presentation materials are available to members only; a login is required.

Join Here